MedX Health Corporation has announced the appointment of Sylvain Desjeans to the company’s board of directors to fill the vacancy created by the retirement of former chairman Rob von der Porten.
Current director Ken McKay has been chosen to replace von der Porten as the new chairman of the MedX Health board. Desjeans, who has more than 30 years of healthcare and pharmaceutical industry experience, was recently promoted to president and CEO of MedX.
“The Board thanks Rob for his service and leadership during a period of over seven years, during which time the Company has developed into being a leading medical device and software company,” new MedX Health chairman McKay said in a statement. “During his tenure, MedX completed the development of its SIAscopy on DermSecure Telemedicine platform."
READ: MedX Health strikes North American distribution deal with VidaCeuticals Health Products
Retiring chairman von der Porten also commented, stating: “I am proud to have worked with my MedX colleagues who are so committed to the development of the SIAscopy technology and the DermSecure Telemedicine platform. It represents a significant leap forward for early detection of skin cancers as well as the assessment of other skin conditions with the addition of its high-definition camera.”
“I am confident that the company will leverage its technology across North America and internationally to achieve great commercial success,” he added.
Headquartered in Mississauga, Ontario, MedX is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology.
SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds.
Contact Sean at sean@proactiveinvestors.com